• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Discovery of Type 3 von Willebrand Disease in a Cohort of Patients with Suspected Hemophilia A in Côte d'Ivoire.在科特迪瓦疑似甲型血友病患者队列中发现3型血管性血友病。
Mediterr J Hematol Infect Dis. 2020 Mar 1;12(1):e2020019. doi: 10.4084/MJHID.2020.019. eCollection 2020.
2
Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?伊朗 2N 型血管性血友病患者能否与甲型血友病患者得到正确区分?他们能否得到恰当的治疗?
Blood Coagul Fibrinolysis. 2020 Sep;31(6):382-386. doi: 10.1097/MBC.0000000000000932.
3
Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.2N型血管性血友病的诊断:一种测量因子VIII与血管性血友病因子结合的简化方法。
Am J Hematol. 1998 Aug;58(4):311-8. doi: 10.1002/(sici)1096-8652(199808)58:4<311::aid-ajh11>3.0.co;2-a.
4
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).使用中间纯度的凝血因子VIII-血管性血友病因子浓缩物(海莫莱士)对2型血管性血友病患者进行大手术时的出血预防。
Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30. doi: 10.1097/00001721-200406000-00006.
5
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.1型/2E型(2A亚型IIE)血管性血友病、1型维琴察型血管性血友病以及由血管性血友病因子基因的D3、D4、B1 - B3和C1 - C2结构域突变引起的轻型1型血管性血友病的实验室诊断。血管性血友病因子多聚体及血管性血友病因子前肽/抗原比值的作用。
Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8.
6
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.2型诺曼底隐性血管性血友病:轻度血友病和1型血管性血友病的可变表现。
Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8.
7
Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.血浆中血管性血友病因子抗原、血管性血友病因子瑞斯托霉素辅因子活性与凝血因子 VIII 活性之间的相关性。
J Thromb Thrombolysis. 2008 Oct;26(2):150-3. doi: 10.1007/s11239-007-0090-0. Epub 2007 Sep 3.
8
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.静脉注射去氨加压素和因子VIII-血管性血友病因子浓缩物用于治疗和预防1型、2型和3型血管性血友病患者的出血。
Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399.
9
Laboratory diagnosis and molecular classification of von Willebrand disease.血管性血友病的实验室诊断与分子分类
Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8.
10
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.隐性严重1型和3型血管性血友病(VWD)、无症状杂合子携带者与血型O相关的血管性血友病因子缺乏症以及显性1型VWD的特征分析
Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. doi: 10.1177/1076029606291401.

引用本文的文献

1
Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension.治疗性Fc融合因子VIII在中性pH下与新生儿Fc受体的结合与半衰期延长不佳有关。
Haematologica. 2025 Jul 1;110(7):1523-1535. doi: 10.3324/haematol.2024.286536. Epub 2024 Dec 12.

本文引用的文献

1
Haemophilia in Côte d'Ivoire (the Ivory Coast) in 2017: Extensive data collection as part of the World Federation of Hemophilia's twinning programme.2017 年科特迪瓦(象牙海岸)的血友病:作为世界血友病联盟结对计划的一部分,进行了广泛的数据收集。
Haemophilia. 2019 Mar;25(2):236-243. doi: 10.1111/hae.13682. Epub 2019 Feb 12.
2
Type-3 von Willebrand disease in India-Clinical spectrum and molecular profile.印度 3 型血管性血友病的临床特征和分子谱。
Haemophilia. 2018 Nov;24(6):930-940. doi: 10.1111/hae.13542. Epub 2018 Jul 8.
3
A 12.3-kb Duplication Within the Gene in Pigs Affected by Von Willebrand Disease Type 3.患3型血管性血友病的猪的基因内一个12.3千碱基的重复序列
G3 (Bethesda). 2018 Feb 2;8(2):577-585. doi: 10.1534/g3.117.300432.
4
Von Willebrand's disease: case report and review of literature.血管性血友病:病例报告及文献综述
Pan Afr Med J. 2017 Jun 29;27:147. doi: 10.11604/pamj.2017.27.147.12248. eCollection 2017.
5
Bleeding risk assessment in hemophilia A carriers from Dakar, Senegal.来自塞内加尔达喀尔的甲型血友病携带者的出血风险评估。
Blood Coagul Fibrinolysis. 2017 Dec;28(8):642-645. doi: 10.1097/MBC.0000000000000653.
6
[Von Willebrand disease type 3 falsely diagnosed as hemophilia A: a case report].[3型血管性血友病被误诊为甲型血友病:一例报告]
Rev Med Brux. 2017;38(1):36-38.
7
Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal.在血友病患者中使用低剂量凝血因子浓缩剂进行包皮环切术:来自塞内加尔达喀尔的经验。
BMC Hematol. 2017 Apr 24;17:8. doi: 10.1186/s12878-017-0080-1. eCollection 2017.
8
Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.血管性血友病及罕见出血性疾病的诊断与治疗
J Clin Med. 2017 Apr 10;6(4):45. doi: 10.3390/jcm6040045.
9
Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia.南非血友病患者女性亲属队列中遗传咨询的接受情况、出血风险知识及心理社会影响
J Genet Couns. 2015 Dec;24(6):978-86. doi: 10.1007/s10897-015-9834-8. Epub 2015 Apr 2.
10
Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.对有无已鉴定出F8突变的A型血友病患者血管性血友病因子表型和基因型的评估。
J Thromb Haemost. 2015 Jun;13(6):1036-42. doi: 10.1111/jth.12902. Epub 2015 May 9.

在科特迪瓦疑似甲型血友病患者队列中发现3型血管性血友病。

Discovery of Type 3 von Willebrand Disease in a Cohort of Patients with Suspected Hemophilia A in Côte d'Ivoire.

作者信息

Adjambri Adia E, Bouvier Sylvie, N'guessan Roseline, N'draman-Donou Emma, Yayo-Ayé Mireille, Meledje Marie-France, Adjé Missa L, Sawadogo Duni

机构信息

Department of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d'Ivoire.

Hematology Unit, Central Laboratory, Yopougon University Hospital, Abidjan, Côte d'Ivoire.

出版信息

Mediterr J Hematol Infect Dis. 2020 Mar 1;12(1):e2020019. doi: 10.4084/MJHID.2020.019. eCollection 2020.

DOI:10.4084/MJHID.2020.019
PMID:32180914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7059751/
Abstract

BACKGROUND

Type 3 von Willebrand disease (VWD) is the most severe form of VWD, characterized by a near-total absence of von Willebrand factor (vWF), leading to a massive deficiency in plasmatic factor VIII (FVIII). VWD may be confused with hemophilia A, sometimes leading to misdiagnosis. The purpose of this work was to finalize the biological diagnosis of patients with FVIII activity deficiency in Abidjan in order to guide the best type of management.

METHODS

We conducted a cross-sectional descriptive study from June 2018 to April 2019. Forty-nine patients, all of whom had lower FVIII levels or had been referred for a bleeding disorder, were monitored in the clinical hematology service. The pro-coagulant activity of coagulation factors was performed in Abidjan. The assays for von Willebrand antigen and activity were performed at Nîmes University Hospital in France.

RESULTS

The mean age of patients was 13.8 years (1 - 65) and 86% were Ivorian. FVIII deficiency was discovered during a biological checkup, circumcision or post-traumatic bleeding, in 33%, 31% and 29% respectively. The FVIII deficiency of patients was classified as severe (89.8%), moderate (8.2%) and mild (2%). Only one patient had a quantitative deficiency of von Willebrand factor (vWF: Ag <3%) with undetectable von Willebrand factor activity (vWF: Ac) and an FVIII level <1%.

CONCLUSIONS

Not all of the congenital deficiency of FVIII are represented by hemophilia A. It was crucial to assess the Willebrand factor of these patients followed in Côte d'Ivoire for whom hemophilia A had been suspected.

摘要

背景

3型血管性血友病(VWD)是血管性血友病最严重的形式,其特征是血管性血友病因子(vWF)几乎完全缺失,导致血浆凝血因子VIII(FVIII)严重缺乏。血管性血友病可能与甲型血友病混淆,有时会导致误诊。这项工作的目的是完成阿比让FVIII活性缺乏患者的生物学诊断,以指导最佳的治疗方式。

方法

我们在2018年6月至2019年4月期间进行了一项横断面描述性研究。49名患者在临床血液科接受监测,所有患者FVIII水平较低或因出血性疾病前来就诊。在阿比让进行凝血因子的促凝活性检测。血管性血友病抗原和活性检测在法国尼姆大学医院进行。

结果

患者的平均年龄为13.8岁(1 - 65岁),86%为科特迪瓦人。分别在血液学检查、包皮环切术或创伤后出血期间发现FVIII缺乏的患者占33%、31%和29%。患者的FVIII缺乏被分类为重度(89.8%)、中度(8.2%)和轻度(2%)。只有一名患者血管性血友病因子定量缺乏(vWF:Ag <3%),血管性血友病因子活性检测不到(vWF:Ac),FVIII水平<1%。

结论

并非所有先天性FVIII缺乏都表现为甲型血友病。对于在科特迪瓦怀疑患有甲型血友病的这些患者,评估其血管性血友病因子至关重要。